FirmAtlas

Company handbook · ABT · Prepared by FirmAtlas · firmatlas.app · printed 2026-10-17

ABT · CIK 1800 · LATEST FILING: 10-Q JUN '26 · FILED JUL 28, 2026

Abbott Laboratories

$104.89 +0.21 (+0.20%)

Close, Oct 16, 2026 · 52-week $82–132

↗ abbott.com

Abbott makes medical devices (heart devices, and diabetes care such as FreeStyle Libre glucose monitors), diagnostic tests and lab instruments, and nutrition products such as Similac, PediaSure and Ensure. It also sells branded generic medicines outside the U.S.

SegmentsMedical Devices 48% · Diagnostic Products 20% · Nutritional Products 19% · Established Pharmaceutical Products 12% (FY25)
RegionsUS 39% · Germany 6% · China 4% · Switzerland 4% · Other 47% (FY25)
CustomersHospitals, labs, doctors, pharmacies and consumers; sold directly to hospitals and labs, and through wholesalers, distributors and retailers
Cash useFY24–FY25: dividends $8.0B · capex $4.4B · buybacks $2.2B
Reinvested 24% of operating cash flow · returned 74% of free cash flow

Last fiscal year

Abbott Laboratories reported revenue of $44.3B for the year ended Dec 31, 2025 (FY25), up 5.7% from FY24. Net income was $6.5B, operating cash flow $9.6B and free cash flow $7.4B. Source: 10-K filed Feb 20, 2026.

Market cap

$183.3B

P/E

29.2

EV/EBITDA

20.1x

P/B

3.5

Div yield

2.40%

ROIC

10.8%

Revenue 1Y

5.7%/yr

EPS 1Y

−51.3%/yr

Shares 1Y

+0.0%

Loading chart…

Daily closes, split-adjusted · ratios at each fiscal year end

Company

CEORobert B. Ford

HQAbbott Park, IL

AuditorErnst & Young LLP

Employees115,000

Year endsDecember

Revenue by segment · FY25

Medical Devices48%

Diagnostic Products20%

Nutritional Products19%

Established Pharmaceutical Products12%

Compounded growth & averages

10Y

TTM

Share price

9.9%

−2.2%

4.4%

−17.8%

Upgrade to see 10 years

Share price: yearly compound rate of the traded close; the last column is the past year.

Where the cash went · FY24–FY25

$14.5B deployed

Capex $4.4B 30.2%

Dividends $8.0B 54.8%

Buybacks $2.2B 15.1%

Operating cash flow over the period: $18.1B. Total debt changed by +$337M. R&D of $5.8B is already inside operating costs.

Sources 10-K FY25 10-Q Jun '26 All filings on EDGAR

Latest filings

Aug 20, 2026 Other announcement 8-K Jul 16, 2026 Quarterly results 8-K Apr 27, 2026 Executive or director change 8-K Apr 17, 2026 Other announcement 8-K Apr 16, 2026 Quarterly results 8-K

Growth engines

How much of the profit growth came from new investment, and how much from running the business better.

Upgrade to see 10 years

Financials

Last 2 years · Upgrade to see 10 years · USD millions · each year opens its 10-K · change vs previous year

Last 4 quarters · USD millions · quarter-end month shown · change vs same quarter a year earlier

TTM = the last four quarters, to Mar '26. Balance-sheet rows show that latest quarter. “—” where the quarters do not add up to the annual figures. No TTM for cash: our quarterly rows do not hold short-term investments yet, and annual cash includes them.

Income

FY24 FY25

TTM

Revenue

41,950

44,328+5.7%

45,134

YoY

+5.7%

Gross profit

23,244

25,009+7.6%

25,393

Gross margin

55.4%

56.4%+1.0 pp

—

Operating income

6,825

8,053+18.0%

7,705

Operating margin

16.3%

18.2%+1.9 pp

—

EBITDA

8,165

9,487+16.2%

—

EBITDA margin

19.5%

21.4%+1.9 pp

—

Interest expense

559

493−11.8%

—

Interest coverage

14.61x

19.24x+4.64x

—

Net income

13,402

6,524−51.3%

6,276

YoY

−51.3%

Net margin

31.9%

14.7%−17.2 pp

—

EPS (diluted, $)

7.64

3.72−51.3%

3.58

YoY

−51.3%

Balance sheet

FY24 FY25

TTM

Total assets

81,414

86,713+6.5%

110,429

Cash & short-term investments

7,967

8,939+12.2%

—

Accounts receivable

6,925

7,929+14.5%

—

Inventory

6,194

6,488+4.7%

—

Net PP&E

10,658

11,816+10.9%

—

Other assets

49,670

51,541+3.8%

—

Total liabilities

33,750

34,583+2.5%

58,368

Total debt

15,625

15,962+2.2%

34,047

Other liabilities

18,125

18,621+2.7%

—

Shareholders’ equity

47,664

52,130+9.4%

52,061

Total liabilities = total assets − shareholders’ equity, so it includes minority interest where a company has one.

Cash flow statement · as filed

FY24 FY25

TTM

Cash from operations

8,558

9,566+11.8%

9,464

Net income

13,402

6,524−51.3%

—

Depreciation & amortization

1,340

1,434+7.0%

—

Stock-based compensation

673

664−1.3%

—

Working capital & other

(6,857)

944n/m

—

Cash from investing

(2,338)

(2,422)n/m

—

Capex

(2,207)

(2,171)n/m

—

Investments bought

(169)

(167)n/m

—

Other investing

(84)−321.1%

—

Cash from financing

(5,404)

(6,309)n/m

—

Dividends

(3,836)

(4,116)n/m

—

Buybacks

(1,295)

(893)n/m

—

Shares issued

264

396+50.0%

—

Other financing

(537)

(1,696)n/m

—

Net change in cash

720

906+25.8%

—

Free cash flow (OCF − capex)

6,351

7,395+16.4%

7,378

Where the cash went

FY24 FY25

TTM

Operating cash flow

8,558

9,566+11.8%

9,464

Reinvested in the business

2,207

2,171−1.6%

—

% of operating cash flow

25.8%

22.7%

Capex

2,207

2,171−1.6%

2,086

R&D (memo, already in costs)

2,844

2,942+3.4%

—

Free cash flow

6,351

7,395+16.4%

7,378

YoY

+16.4%

Returned to shareholders

5,131

5,009−2.4%

—

% of free cash flow

80.8%

67.7%

Dividends

3,836

4,116+7.3%

—

Buybacks

1,295

893−31.0%

—

Change in total debt

—

337

—

Cash left over

—

2,723

—

FCF conversion (FCF ÷ net income)

47.4%

113.4%+66.0 pp

—

Owner earnings

—

4,489

—

Owner earnings margin

—

10.1%

—

Buyback yield

0.7%

0.4%−0.2 pp

—

Returns & ratios

FY24 FY25

TTM

ROIC (all capital)

12.3%

10.8%−1.5 pp

—

ROIC (operating)

28.7%

24.8%−3.9 pp

—

Net debt / EBITDA

0.94x

0.74x−0.20x

—

Debt / equity

0.33x

0.31x−0.02x

—

ROE

28.1%

12.5%−15.6 pp

—

ROA

16.5%

7.5%−8.9 pp

—

ROCE

10.1%

11.5%+1.3 pp

—

NOPAT

6,825

6,206−9.1%

—

Invested capital (operating)

23,777

26,233+10.3%

—

Invested capital (all)

55,322

59,153+6.9%

—

Reinvestment rate

—

39.6%

—

Debtor days

65+5 d

—

Inventory days

121

123+2 d

—

Income

Jun '25

Sep '25

Dec '25

Mar '26

Revenue

11,142

11,369

11,459

11,164

vs year-ago quarter

Gross profit

6,288

6,294

6,537

6,274

Gross margin

56.4%

55.4%

57.0%

56.2%

Operating income

2,052

2,057

2,251

1,345

Net income

1,779

1,644

1,776

1,077

vs year-ago quarter

Net margin

16.0%

14.5%

15.5%

9.6%

EPS (diluted, $)

1.01

0.94

1.02

0.61

vs year-ago quarter

Balance sheet

Jun '25

Sep '25

Dec '25

Mar '26

Total assets

83,999

84,181

86,713

110,429

Cash & equivalents

6,951

7,511

8,939

6,803

Total debt

13,437

12,941

15,962

34,047

Shareholders’ equity

50,565

50,954

52,130

52,061

Cash flow

Jun '25

Sep '25

Dec '25

Mar '26

Operating cash flow

2,047

2,787

3,315

1,315

Capex

502

496

689

399

Free cash flow

1,545

2,291

2,626

916

vs year-ago quarter